Sign in
ASLN Stock Price, Chart, Stats & News
ASLAN Pharmaceuticals Limited
Save
777.12M
Market cap
–
Current P/E
–
Forward P/E
ASLN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 97.10% |
Operating margin | -364.46% |
Pretax margin | -367.39% |
Net margin | -368.50% |
Effective tax rate | -0.30% |
ROA | -179.56% |
ROE | 1796.92% |
D/E | -2.02x |
Interest coverage ratio | -10.11x |
ASLN valuation
P/E | – |
P/S | 64.76x |
P/B | -0.19x |
P/CF | -0.05x |
P/FCF | -16.76x |
P/OCF | -0.05x |
PEG | -0.00x |
EV multiple | -19.58x |
About
ASLAN Pharmaceuticals Limited is a biopharmaceutical firm operating at the clinical stage, primarily focused on immunology, and dedicated to creating innovative treatments that profoundly enhance patients' lives. Its advanced therapeutic pipeline features ASLAN004, a monoclonal antibody currently being evaluated for atopic dermatitis and a range of other immunological disorders. Also under development is ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase, intended to treat autoimmune conditions.
Similar securities
Based on sector and market capitalization
Report issue